N-(3,4-dimethylphenyl)-2-oxo-3,4-dihydro-1H-quinoline-6-sulfonamide profile

ID Source	ID
PubMed CID	4547230
CHEMBL ID	1509101
CHEBI ID	93365
SCHEMBL ID	1711251

Synonym
n-(3,4-dimethylphenyl)-2-oxo-1,2,3,4-tetrahydroquinoline-6-sulfonamide
MLS000673795
smr000315036
NCGC00185939-01
ml170
SNFROMRRGGKYTF-UHFFFAOYSA-N ,
AKOS002118043
n-(3,4-dimethylphenyl)-2-oxo-3,4-dihydro-1h-quinoline-6-sulfonamide
HMS2709H11
bdbm50361555
CHEMBL1509101 ,
SCHEMBL1711251
CHEBI:93365
899717-26-1
Q27165071
ml-170

Excerpt	Reference	Relevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51

Class	Description
quinolines	A class of aromatic heterocyclic compounds each of which contains a benzene ring ortho fused to carbons 2 and 3 of a pyridine ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (9)

Potency Measurements

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE	Homo sapiens (human)	Potency	31.6228	0.0032	45.4673	12,589.2998	AID2517
glp-1 receptor, partial	Homo sapiens (human)	Potency	11.2202	0.0184	6.8060	14.1254	AID624417
ATAD5 protein, partial	Homo sapiens (human)	Potency	25.9185	0.0041	10.8903	31.5287	AID504467
TDP1 protein	Homo sapiens (human)	Potency	29.0929	0.0008	11.3822	44.6684	AID686978
aldehyde dehydrogenase 1 family, member A1	Homo sapiens (human)	Potency	12.5893	0.0112	12.4002	100.0000	AID1030
nuclear factor erythroid 2-related factor 2 isoform 2	Homo sapiens (human)	Potency	23.1093	0.0041	9.9848	25.9290	AID504444
pyruvate kinase PKM isoform a	Homo sapiens (human)	Potency	0.4083	0.0401	7.4590	31.6228	AID1631; AID1634; AID1751; AID2533; AID2576; AID624389; AID624391
DNA polymerase iota isoform a (long)	Homo sapiens (human)	Potency	89.1251	0.0501	27.0736	89.1251	AID588590
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Pyruvate kinase PKM	Homo sapiens (human)	EC50 (µMol)	0.7900	0.0005	0.5920	6.0000	AID639784
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (6)

Process	via Protein(s)	Taxonomy
programmed cell death	Pyruvate kinase PKM	Homo sapiens (human)
canonical glycolysis	Pyruvate kinase PKM	Homo sapiens (human)
positive regulation of sprouting angiogenesis	Pyruvate kinase PKM	Homo sapiens (human)
positive regulation of cytoplasmic translation	Pyruvate kinase PKM	Homo sapiens (human)
glycolytic process	Pyruvate kinase PKM	Homo sapiens (human)
cellular response to insulin stimulus	Pyruvate kinase PKM	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Process	via Protein(s)	Taxonomy
magnesium ion binding	Pyruvate kinase PKM	Homo sapiens (human)
RNA binding	Pyruvate kinase PKM	Homo sapiens (human)
mRNA binding	Pyruvate kinase PKM	Homo sapiens (human)
protein tyrosine kinase activity	Pyruvate kinase PKM	Homo sapiens (human)
pyruvate kinase activity	Pyruvate kinase PKM	Homo sapiens (human)
protein binding	Pyruvate kinase PKM	Homo sapiens (human)
ATP binding	Pyruvate kinase PKM	Homo sapiens (human)
MHC class II protein complex binding	Pyruvate kinase PKM	Homo sapiens (human)
potassium ion binding	Pyruvate kinase PKM	Homo sapiens (human)
cadherin binding	Pyruvate kinase PKM	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (13)

Process	via Protein(s)	Taxonomy
extracellular region	Pyruvate kinase PKM	Homo sapiens (human)
nucleus	Pyruvate kinase PKM	Homo sapiens (human)
cytoplasm	Pyruvate kinase PKM	Homo sapiens (human)
mitochondrion	Pyruvate kinase PKM	Homo sapiens (human)
rough endoplasmic reticulum	Pyruvate kinase PKM	Homo sapiens (human)
cytosol	Pyruvate kinase PKM	Homo sapiens (human)
cilium	Pyruvate kinase PKM	Homo sapiens (human)
vesicle	Pyruvate kinase PKM	Homo sapiens (human)
secretory granule lumen	Pyruvate kinase PKM	Homo sapiens (human)
collagen-containing extracellular matrix	Pyruvate kinase PKM	Homo sapiens (human)
extracellular exosome	Pyruvate kinase PKM	Homo sapiens (human)
extracellular vesicle	Pyruvate kinase PKM	Homo sapiens (human)
ficolin-1-rich granule lumen	Pyruvate kinase PKM	Homo sapiens (human)
cytoplasm	Pyruvate kinase PKM	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (22)

Assay ID	Title	Year	Journal	Article
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID639794	Apparent permeability from apical to basolateral side of human Caco2 cells at pH 7.4 after 2 hrs by LC/MS/MS analysis	2011	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21	2-Oxo-N-aryl-1,2,3,4-tetrahydroquinoline-6-sulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase.
AID639789	Activation of PKM1 assessed as ATP product formation at 57.5 uM after 1 hr by luminescent pyruvate kinase-luciferase coupled assay	2011	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21	2-Oxo-N-aryl-1,2,3,4-tetrahydroquinoline-6-sulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase.
AID639784	Activation of human PKM2 assessed as ATP product formation after 1 hr by luminescent pyruvate kinase-luciferase coupled assay	2011	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21	2-Oxo-N-aryl-1,2,3,4-tetrahydroquinoline-6-sulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase.
AID639796	Efflux ratio of permeability from apical to basolateral side over basolateral to apical side in human Caco2 cells at pH 7.4 after 2 hrs by LC/MS/MS analysis	2011	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21	2-Oxo-N-aryl-1,2,3,4-tetrahydroquinoline-6-sulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase.
AID639792	Half life in human liver microsomes at 2 uM after 2 mins by LC/MS/MS analysis	2011	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21	2-Oxo-N-aryl-1,2,3,4-tetrahydroquinoline-6-sulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase.
AID639793	Half life in mouse liver microsomes at 2 uM after 2 mins by LC/MS/MS analysis	2011	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21	2-Oxo-N-aryl-1,2,3,4-tetrahydroquinoline-6-sulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase.
AID639795	Apparent permeability from basolateral to apical side of human Caco2 cells at pH 7.4 after 2 hrs by LC/MS/MS analysis	2011	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21	2-Oxo-N-aryl-1,2,3,4-tetrahydroquinoline-6-sulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (14.29)	29.6817
2010's	5 (71.43)	24.3611
2020's	1 (14.29)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	7 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes
N-(4-methylphenyl)-2-oxo-3,4-dihydro-1H-quinoline-6-sulfonamide [no description available]	2.06	1	quinolines
N-(3-methylphenyl)-2-oxo-3,4-dihydro-1H-quinoline-6-sulfonamide [no description available]	2.06	1	quinolines
N-(4-fluorophenyl)-2-oxo-3,4-dihydro-1H-quinoline-6-sulfonamide [no description available]	2.06	1	quinolines
6-[(3-methoxyphenyl)methyl]-4-methyl-2-methylsulfinyl-5-thieno[3,4]pyrrolo[1,3-d]pyridazinone [no description available]	2.06	1	organic heterobicyclic compound; organonitrogen heterocyclic compound; organosulfur heterocyclic compound
3-[[4-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)-1,4-diazepan-1-yl]sulfonyl]aniline [no description available]	2.06	1	benzenes; sulfonamide

Condition	Relationship Strength	Studies
Innate Inflammatory Response [description not available]	2.05	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.05	1
Benign Neoplasms [description not available]	2.06	1
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	2.06	1

N-(3,4-dimethylphenyl)-2-oxo-3,4-dihydro-1H-quinoline-6-sulfonamide

Cross-References

Synonyms (16)

Research Excerpts

Bioavailability

Drug Classes (1)

Protein Targets (9)

Potency Measurements

Activation Measurements

Biological Processes (6)

Molecular Functions (10)

Ceullar Components (13)

Bioassays (22)

Research

Studies (7)

Market Indicators

Research Demand Index: 12.29

Study Types

N-(3,4-dimethylphenyl)-2-oxo-3,4-dihydro-1H-quinoline-6-sulfonamide

Cross-References

Synonyms (16)

Research Excerpts

Bioavailability

Drug Classes (1)

Protein Targets (9)

Potency Measurements

Activation Measurements

Biological Processes (6)

Molecular Functions (10)

Ceullar Components (13)

Bioassays (22)

Research

Studies (7)

Market Indicators

Research Demand Index: 12.29

Study Types

Related Drugs (5)

Related Conditions (4)